Emmanuel Caeymaex - UCB SA President
| UCBJF Stock | USD 190.00 1.00 0.52% |
President
Mr. Emmanuel Caeymaex has served as Executive Vice President, Immunology Patient Value Unit Head, Member of the Executive Committee of UCB S.A. since February 2015. He joined UCB in March 1994. He leads the understanding of patient needs, the development and commercialization of solutions which create value for people suffering from autoimmune disorders such as bowel diseases, skin conditions and lupus. Over the last 20 years Emmanuel was instrumental in advancing UCBs transformation into a global company focused on patients with severe diseases. Prior to this appointment he led the Cimzia Global Patient Solutions team. Emmanuel formerly served as President of UCB Japan Co Ltd. from September 2006 to June 2011 and on the Global Operations Committee. He previously contributed to build UCBs leadership position in epilepsy, successively as Global Brand Manager Keppra, UK Business Unit Head, and Vice President Global Marketing for Central Nervous System products. Prior to 1999, Emmanuel established and ran UCBs operations in several AsiaPacific markets for which he was awarded as Laureate of the Prince Albert Fund. He received a Business Engineer MS degree from Universite Catholique de Louvaine, Belgium, a Masters in International Management from the Global Alliance in Management Education and was continuing his executive leadership development journey at INSEAD. since 2015.
| Age | 54 |
| Tenure | 10 years |
| Phone | 32 2 559 99 99 |
| Web | https://www.ucb.com |
UCB SA Management Efficiency
The company has return on total asset (ROA) of 0.0468 % which means that it generated a profit of $0.0468 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1069 %, meaning that it generated $0.1069 on every $100 dollars invested by stockholders. UCB SA's management efficiency ratios could be used to measure how well UCB SA manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Raquel Izumi | Vincerx Pharma | 55 | |
| Juan Jaen | Arcus Biosciences | 67 | |
| Robb Knie | Hoth Therapeutics | 56 | |
| Kanya MD | Senti Biosciences | 51 | |
| Massimo MBA | Jaguar Animal Health | 67 | |
Management Performance
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 |
UCB SA Leadership Team
Elected by the shareholders, the UCB SA's board of directors comprises two types of representatives: UCB SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UCB. The board's role is to monitor UCB SA's management team and ensure that shareholders' interests are well served. UCB SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UCB SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sandrine CFA, Ex CFO | ||
| Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head | ||
| William Silbey, Exec Counsel | ||
| Pr LowFriedrich, Chief VP | ||
| Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee | ||
| Kirsten LundJurgensen, Ex Solutions | ||
| Caroline Vancoillie, Chief Functions | ||
| JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee | ||
| JeanChristophe Tellier, Chairman of the Executive Committee, CEO |
UCB Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is UCB SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.11 | |||
| Return On Asset | 0.0468 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.19 % | |||
| Current Valuation | 17.07 B | |||
| Shares Outstanding | 189.96 M | |||
| Shares Owned By Insiders | 38.03 % | |||
| Shares Owned By Institutions | 40.78 % | |||
| Price To Earning | 17.62 X | |||
| Price To Book | 1.52 X |
Currently Active Assets on Macroaxis
Other Information on Investing in UCB Pink Sheet
UCB SA financial ratios help investors to determine whether UCB Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in UCB with respect to the benefits of owning UCB SA security.